Penrazol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Penrazol

What is Penrazol? (Omeprazole)

Property Description
Active ingredient Omeprazole
Form Delayed-release capsules, Enteric-coated tablets
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Suppression of gastric acid output
Origin Synthetic, Substituted benzimidazole derivative

Defining the Pharmacological Class

Penrazol is a specific medication containing the active pharmaceutical ingredient (API) Omeprazole, a synthetic substituted benzimidazole derivative. It is classified as a Proton Pump Inhibitor (PPI), an established form of anti-ulcer agent. This classification identifies the drug as a powerful agent for managing conditions related to excessive stomach acid production. The clinical utility of PPIs, including Omeprazole, involves controlling gastric acid secretion. This medication provides a reliable, sustained reduction in the production of stomach acid, a benefit unique compared to temporary relief provided by antacids.

Composition, Form, and Anti-Secretory Purpose

The formulation of Penrazol is critical due to the acid-labile property of Omeprazole, meaning the compound would be degraded by the stomach's acid. For this reason, the drug is supplied as delayed-release capsules or enteric-coated tablets intended for oral administration, a design that ensures the active ingredient is absorbed in the small intestine. The primary physiological effect is the potent inhibition of gastric acid secretion. The general purpose is to leverage this strong anti-secretory action to create a consistently low-acid environment, which facilitates the healing of tissues irritated or damaged by corrosive stomach acid.

Regulatory References

  1. excessive stomach acid production
  2. oral administration

What side effects are possible with Penrazol?

Official Safety Profile and Adverse Reactions

The safety profile of Penrazol (Omeprazole) is formally documented in government regulatory materials, classifying potential adverse reactions by their physiological system and observed frequency. The most Common events, affecting the gastrointestinal tract and nervous system, include headache, abdominal pain, constipation, diarrhea, flatulence, and nausea or vomiting.

Less frequently, Uncommon reactions may involve the nervous system (e.g., dizziness, somnolence) or the skin (e.g., rash, pruritus), and a documented increase in liver enzymes.

Serious and Duration-Related Safety Concerns

The medicine is associated with Rare but serious adverse reactions, which include hypersensitivity reactions (such as anaphylaxis or angioedema) and certain blood dyscrasias (e.g., leukopenia). Very Rare documented events include severe cutaneous adverse reactions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Official labels note specific risks tied to long-term exposure (typically one year or more). These risks include an association with increased potential for osteoporosis-related fractures of the hip, wrist, or spine. Additionally, the risk of hypomagnesaemia (low magnesium levels) is primarily noted with prolonged use. The label also notes that the medicine is contraindicated in patients with a known hypersensitivity to the drug or other substituted benzimidazoles, as well as for concomitant use with the antiviral drug nelfinavir.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Penrazol (Omeprazole) based on reported clinical manifestations and mandated emergency actions. Overdosage, which has been reported with doses ranging from 320 mg to 900 mg, typically presents with a specific set of documented symptoms.


Documented Overdose Manifestations

System Reported Signs and Symptoms
Central Nervous System Confusion, Drowsiness, Headache, Blurred vision
Cardiovascular Tachycardia (rapid heart rate)
Systemic Nausea, Diaphoresis (increased sweating), Flushing, Dry mouth

Required Emergency Actions

The regulatory assessment indicates that while symptoms such as confusion and tachycardia may occur, these manifestations are generally transient, and no serious clinical outcome has been reported in connection with overdosage. Regardless of symptom severity, seeking medical attention is required to facilitate professional management.

Management must be symptomatic and supportive, as no specific antidote for omeprazole overdosage is known. Furthermore, official prescribing information notes that the medication is not readily dialyzable due to its extensive protein binding, a critical consideration for medical treatment.

Therapeutic Uses of Penrazol

What Penrazol Treats: Main Uses and Benefits

Penrazol is a medication commonly used in the management of conditions related to systemic imbalance, such as those involving inflammatory or irritative processes. The use of Penrazol involves providing symptomatic assistance in related conditions. This supportive approach generally helps ease the overall symptom load.

The medication is relevant for managing symptoms associated with acute or episodic changes and is used for conditions presenting with disruptive symptom manifestations. These uses often address symptoms that interfere with daily functioning and those that become more disruptive during flare-ups. Penrazol is particularly helpful in clinical settings where short-term symptomatic assistance is needed to help stabilize temporary discomfort.

Penrazol plays a role in managing symptoms that contribute to distress. The support provided may assist with maintaining functional stability. The medication may assist with easing groups of symptoms that may appear suddenly or intensify over time.


Quick Fact Block

Quick Fact: Relief for Symptomatic Discomfort

Key Therapeutic Domains

The medication is relevant in situations involving symptoms associated with acute or episodic changes, applied in contexts involving heightened physiological activity, and assisting with the management of daily symptom interference.

Eligibility and Restrictions for Use

Who can and cannot use Penrazol?

Penrazol (omeprazole) eligibility is strictly defined by regulatory authorities based on population-specific limitations and absolute prohibitions. Use is contraindicated for patients with a known hypersensitivity to omeprazole, the substituted benzimidazole class, or any excipients in the formulation. Use is also prohibited for patients taking concomitant medication containing rilpivirine.

Age-Group Eligibility:

  • Infants under 1 year of age are generally not recommended or contraindicated for use, and safety has not been established for infants under one month.
  • Adults (18+ years) are approved for all labeled uses.
  • Older adults do not typically require a general dose adjustment.

Special Population Restrictions:

  • Patients with severe hepatic impairment require caution as dose adjustment may be necessary due to impaired metabolism.
  • The medicine is not recommended during breastfeeding due to excretion in breast milk, but is permitted during pregnancy when clinically necessary, as available data do not indicate risk of fetal harm.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Penrazol is documented to interact with other medicines through several primary mechanisms. The most significant interactions involve medicines that are metabolized by Cytochrome P450 (CYP) enzymes, particularly CYP3A4, or those that affect drug transporter systems like P-glycoprotein.

Documented Interaction Categories

Category Regulatory Constraint
Strong CYP3A4 Inducers (e.g., Rifampin, St. John's Wort) Contraindicated due to significant reduction of Penrazol effectiveness.
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir) May significantly increase exposure to Penrazol; requires close monitoring or dose adjustment.
Sensitive CYP3A4 Substrates (e.g., certain statins, cyclosporine) Penrazol may increase exposure to the co-administered drug; requires dose limitation or monitoring.
Acid-Reducing Agents (e.g., Antacids, H2-Blockers) Requires timing constraints for administration to ensure proper Penrazol absorption.
Warfarin and other Vitamin K Antagonists Requires frequent monitoring of International Normalized Ratio ( INR) upon initiation or discontinuation of Penrazol.

These constraints ensure patient safety by managing changes in medicine concentration. Regulatory documents emphasize that concomitant use of Penrazol with strong CYP3A4 inducers is prohibited. For other interacting medicines, adjustments to the co-administered medicine's dose or close laboratory monitoring are official requirements.

Mechanism of Action

How Penrazol Works

Irreversible Enzyme Inhibition

This mechanism centers on Penrazol's primary biological target: the H^+/ K^+- ATPase enzyme, commonly known as the Proton Pump, found on the surface of the stomach's parietal cells. Penrazol is an inactive prodrug that is selectively activated by the acidic environment near the target enzyme. Its activated form then creates a covalent, irreversible bond with the Proton Pump, permanently disabling it and acting as an upstream blocker of acid production.


Modulating Gastric Acid Secretion

This interaction directly interrupts the final step of the gastric acid secretion pathway, preventing the transport of hydrogen ions ( H^+) into the stomach lumen. This results in a long-duration decrease in the output of hydrochloric acid, leading to a significant elevation of gastric pH (lowered acidity). Because the inhibition is permanent, the anti-acid effect lasts until the acid-producing cells synthesize new Proton Pump molecules, ensuring consistent reduction of gastric acidity over time.

Dosage and Administration Information

Penrazol (Omeprazole) is administered through the oral route, with specific administration principles derived from the medicine's acid-labile properties. The delayed-release formulation is designed to protect the active ingredient from stomach acid; therefore, capsules or tablets must be swallowed whole and should never be chewed, crushed, or split, as this compromises the protective enteric coating.

Dosing and Scheduling

The administration schedule is typically once daily, recommended to be taken before eating (before a meal) to optimize its anti-secretory action. Standard daily doses for short-term courses commonly range from 20 mg to 40 mg. For conditions requiring high-level acid suppression, such as pathological hypersecretory conditions, the starting daily dose is 60 mg. Total daily doses exceeding 80 mg are administered in divided doses (e.g., twice daily).

Duration and Adjustments

The duration of use is generally short-term, most commonly ranging from 4 to 8 weeks. Long-term use is restricted to specific indications, such as maintenance therapy for healing or chronic hypersecretory conditions. Dosing adjustments apply to patients with hepatic impairment, where a lower dose of 10 mg to 20 mg may be sufficient. Dosing adjustments are not typically required for patients with renal impairment.

Recent Clinical Evidence

Penrazol: Overview of Clinical Studies

This overview summarizes the research evidence base used to evaluate Penrazol, focusing strictly on the types of studies conducted and the outcomes that were examined, without providing clinical advice or treatment claims.


Evidence for Healing of Erosive Esophagitis

Research exploring the use of Penrazol for erosive esophagitis primarily consists of Randomized Controlled Trials (RCTs) with defined observation periods. These studies were designed to examine outcomes related to tissue repair. Researchers monitored patients to evaluate the physical characteristics of the lining of the esophagus, often using visual assessment methods. Findings from these trials describe patterns observed in the studies related to measurements of physical healing endpoints evaluated by visual assessment.

For patients who reached a predefined study endpoint, further Maintenance RCTs were conducted, examining the rate of recurrence of tissue changes over periods up to a year. Despite the available data, there is limited information for long-term outcomes that extend beyond one year, and data for pediatric subgroups remain insufficient regarding long-term effects.

Evidence for Symptomatic Gastroesophageal Reflux Disease (GERD)

Research examined symptomatic GERD, a condition associated with acute episodes, utilizing randomized, double-blinded trials and observational settings. Studies explored outcomes related to physical discomfort, specifically monitoring the frequency and severity of heartburn. Studies explored patterns related to the reported discomfort in the observed populations compared to comparators. The research provides context about changes in symptom frequency, but there is limited information for the appropriate duration of use for symptom control in patients who do not exhibit erosive tissue damage.

Key Research Gaps and Uncertainties

The existing evidence highlights that the research is limited in several key areas. First, there is limited information for long-term outcomes extending beyond the initial controlled trial phases. Second, for certain indications like Acid Peptic Disease Symptoms, the evidence quality varies across studies. Third, data for certain subgroups, such as complex comorbid populations, remain insufficient, and results apply only to the populations studied in the pivotal research.

Frequently Asked Questions (FAQ)

Common questions about Penrazol (FAQ)

Q: How quickly does Penrazol start working after you take it?

Official documents describe the beginning of the medicine's anti-acid effect as occurring within one hour after it is taken orally. The maximum effect on acid suppression is generally seen within about two hours after administration.


Q: How long do the effects of Penrazol last?

The ability of Penrazol to inhibit acid production is noted to be long-lasting because it permanently binds to the acid-producing enzyme. Official information states that the effects of a dose on acid secretion can persist for up to 72 hours, or three days.


Q: Does Penrazol interact with common pain relievers like ibuprofen?

Primary regulatory interaction summaries do not typically list common non-steroidal anti-inflammatory drugs ( NSAIDs) like ibuprofen as primary interactions. However, official warnings do exist regarding the use of NSAIDs due to their potential for irritating the stomach lining, which is a condition Penrazol is prescribed to help manage.


Q: Is Penrazol considered a controlled substance?

According to official regulatory drug classification records, Penrazol (Omeprazole) is not scheduled or designated as a controlled substance by government authorities.


Q: Can Penrazol cause changes in appetite or weight?

While changes in appetite are not listed among the most common effects, official safety reports include documented events related to anorexia (loss of appetite) and a documented increase in weight. These events are noted in post-marketing experience summaries.


Q: What happens if I forget to take a dose of Penrazol?

Information found in patient resources and official product guidance generally describes two approaches for a missed dose. If a dose is recalled soon, it can be taken. However, if the next scheduled dose is approaching, the instruction is often to skip the missed dose and resume the usual schedule, avoiding taking two doses closely together.


Q: What should I do if a side effect of Penrazol bothers me?

Regulatory documents state that any serious or rare adverse reactions are typically reported immediately to a healthcare professional. For common side effects that continue or cause discomfort, official guidance suggests reporting the event to a healthcare professional for evaluation.


Q: Does Penrazol make you feel tired or sleepy?

The official safety profile of the medicine lists that somnolence (drowsiness) is an Uncommon side effect. Furthermore, events related to general fatigue (tiredness) and dizziness are also officially documented.


Q: Is it normal to have a slight headache when starting Penrazol?

Headache is formally classified as a Common adverse reaction, meaning it is one of the more frequently observed events reported in patients. Official regulatory sources classify this event based on frequency but do not detail the typical time of onset.


Q: Can I take Penrazol if I'm already taking a supplement like magnesium?

Official warnings note a risk of developing hypomagnesaemia (low magnesium levels) with prolonged use of Penrazol. Official caution is noted for patients taking other medicines or supplements that can affect magnesium balance, and the need for monitoring is determined by a healthcare professional.


Q: Is there a generic version of Penrazol available?

Yes, regulatory and official drug product databases confirm that Penrazol, which contains the active ingredient Omeprazole, is widely available in many countries as a generic formulation approved by official government agencies.


Q: What is Penrazol used for besides its main purpose?

Beyond the uses for GERD and esophagitis, regulatory documents list other official indications. These include treatment of duodenal and gastric ulcers, for use in combination with antibiotics to help eradicate extitH. pylori infection, and for treating the condition known as Zollinger-Ellison syndrome.


Q: Does Penrazol have any long-term effects on the body?

Official safety labels describe specific risks associated with use lasting one year or more. These include an association with an increased potential for osteoporosis-related fractures and low magnesium levels (hypomagnesaemia). Other potential long-term issues, such as extitC. difficile-associated diarrhea, are also noted in official warnings.


Q: Can Penrazol affect my mood or cause anxiety?

The official safety profile notes rare psychiatric events documented in post-marketing reports, including confusion, agitation, and depression. These types of events related to mood and nervous system function are classified as Rare.


Q: How does Penrazol affect the liver or kidneys?

Regulatory information indicates that uncommon reactions include documented increases in liver enzyme levels. Regarding the kidneys, official safety reports have rarely documented an inflammatory kidney condition called acute interstitial nephritis. Patients with severe hepatic impairment may require dose adjustment.


Q: Is it safe to drink alcohol in moderation while on Penrazol?

Authoritative patient guidance generally suggests that alcohol does not significantly interact chemically with the medicine. However, because alcohol is known to increase stomach acid production, it may potentially worsen the acid reflux symptoms the medicine is intended to manage.


Q: Has Penrazol been linked to any withdrawal symptoms?

While the medicine is not associated with typical withdrawal symptoms, published observational data consistent with regulatory review indicates that stopping long-term use may result in a temporary increase in acid production, which is referred to as rebound acid hypersecretion.


Q: Are there any warnings about taking Penrazol before surgery?

Guidance reviewed by official bodies indicates that continuation of the medicine is generally suggested for most elective surgery procedures. However, use is typically reviewed by a healthcare professional if the patient is undergoing specific anti-reflux surgeries or certain diagnostic tests.


Q: Can Penrazol cause skin sensitivity to the sun?

The official safety profile is consistent with documented reports of increased sensitivity of the skin to sunlight, a condition known as photosensitivity. This event has been noted during postmarketing experience.


Q: Are there different strengths of Penrazol available?

Yes, official prescribing information notes that the medicine is manufactured and available in various dosage strengths for oral use. These commonly include 10 mg, 20 mg, and 40 mg capsules or tablets.


Q: What is the typical age range of patients who use Penrazol?

Regulatory documents confirm that the medicine is approved for use in both adults and pediatric patients for certain labeled uses. Approved pediatric age ranges can extend from 1 year of age up to 16 years for some specific indications.


Q: Is Penrazol used for acute problems or long-term management?

The medicine is officially indicated for both short-term courses, typically ranging from 4 to 8 weeks for acute healing of conditions like erosive esophagitis, and for long-term maintenance therapy for specific chronic conditions.


Q: How soon after stopping Penrazol do the effects wear off?

Official pharmacodynamic data notes that after the medicine is discontinued, the normal ability of the stomach to secrete acid returns gradually. This gradual return to pre-treatment acid production levels typically occurs over a period of about 3 to 5 days.


Q: Does Penrazol have an official warning about allergic reactions?

Yes, a known hypersensitivity to Penrazol or related compounds is listed as a formal contraindication in regulatory documents. Furthermore, severe allergic reactions such as anaphylaxis are noted as Rare but serious adverse reactions that require immediate medical attention.

How should Penrazol be stored and disposed of?

How to Store and Dispose of Penrazol

Penrazol must be stored at controlled room temperature, maintaining a range between 20 C and 25 C (68 F and 77 F), with permitted brief temperature excursions up to 30 C. The medicine requires specific environmental protection to maintain product integrity.

Storage and Protection Requirements

Requirement Instruction
Temperature Store between 20 C and 25 C.
Protection Must be protected from light and moisture and kept in the original, tightly closed container.
Child Safety Keep Penrazol and all medicines out of the sight and reach of children.

Stability and Disposal

Any mixed or reconstituted product must be discarded immediately and not stored for later use, according to official stability rules. Disposal of expired or unused Penrazol should be conducted in compliance with local requirements, typically through a drug take-back program, and must not be discarded via wastewater or general household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Penrazol found in:

A-Z Index: